Profile data is unavailable for this security.
About the company
Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers. The Company encompasses that inhibitors of protein phosphatases have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. It is focused on development activities of its LB-100 series of drugs. The LB-100 series have activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.
- Revenue in USD (TTM)0.00
- Net income in USD-4.69m
- Incorporated2005
- Employees3.00
- LocationLixte Biotechnology Holdings IncNo. 2, 248 Route 25AEAST SETAUKET 11733United StatesUSA
- Phone+1 (310) 203-2902
- Fax+1 (928) 982-5050
- Websitehttps://lixte.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genprex Inc | 0.00 | -27.63m | 5.35m | 26.00 | -- | 0.5599 | -- | -- | -19.18 | -19.18 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -153.97 | -92.06 | -202.83 | -98.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.99 | -- | -7.13 | -- |
Emmaus Life Sciences Inc | 28.46m | -4.74m | 5.36m | 55.00 | -- | -- | -- | 0.1885 | -0.0931 | -0.0931 | 0.3905 | -0.6773 | 0.6349 | 0.8184 | 9.36 | 517,454.50 | -10.58 | -- | -- | -- | 93.69 | -- | -16.66 | -- | 0.1249 | 0.1426 | -- | -- | -10.77 | -- | 33.37 | -- | -- | -- |
Stemtech Corp | 4.64m | -4.08m | 5.40m | 45.00 | -- | -- | -- | 1.16 | -0.0624 | -0.0624 | 0.0619 | -0.0092 | 1.09 | 8.35 | 65.16 | 103,098.40 | -96.70 | -- | -- | -- | 76.09 | -- | -88.58 | -- | 0.1045 | -1.81 | 2.27 | -- | -- | -- | -- | -- | -- | -- |
MyMD Pharmaceuticals Inc | 0.00 | -7.07m | 5.42m | 9.00 | -- | 0.2397 | -- | -- | -5.53 | -5.53 | 0.00 | 10.28 | 0.00 | -- | -- | 0.00 | -25.59 | -76.20 | -31.13 | -84.38 | -- | 7.64 | -- | -4,290.96 | -- | -- | 0.00 | -- | -- | -- | 49.15 | -- | -- | -- |
Biofrontera Inc | 34.07m | -20.13m | 5.45m | 85.00 | -- | 0.3388 | -- | 0.1598 | -15.19 | -15.19 | 24.30 | 3.16 | 0.8646 | 1.93 | 5.42 | 400,858.80 | -51.08 | -- | -101.07 | -- | 48.80 | -- | -59.08 | -- | 0.6727 | -2.71 | 0.4489 | -- | 18.82 | -- | -3,045.47 | -- | -- | -- |
Lixte Biotechnology Holdings Inc | 0.00 | -4.69m | 5.53m | 3.00 | -- | -- | -- | -- | -2.38 | -2.38 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -118.45 | -104.18 | -130.17 | -111.05 | -- | -- | -- | -- | -- | -1,253.20 | 0.00 | -- | -- | -- | 19.41 | -- | -- | -- |
Xenetic Biosciences Inc | 2.44m | -4.47m | 5.56m | 4.00 | -- | 0.6407 | -- | 2.27 | -2.92 | -2.92 | 1.59 | 5.63 | 0.2116 | -- | -- | 611,240.00 | -38.71 | -48.91 | -41.54 | -52.82 | -- | -- | -182.95 | -682.42 | -- | -- | 0.00 | -- | 48.80 | -- | 36.90 | -- | -- | -- |
Fresh Tracks Therapeutics Inc | 8.01m | -5.69m | 5.58m | 4.00 | -- | 0.5615 | -- | 0.6965 | -1.38 | -1.38 | 1.49 | 1.66 | 0.7326 | -- | -- | 2,001,500.00 | -52.10 | -89.76 | -66.50 | -115.24 | -- | -- | -71.12 | -442.61 | -- | -1,272.00 | 0.00 | -- | 15.31 | 37.62 | 73.02 | -- | -- | -- |
Processa Pharmaceuticals Inc | 0.00 | -9.83m | 5.60m | 13.00 | -- | 0.6301 | -- | -- | -6.29 | -6.29 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -87.82 | -84.35 | -102.32 | -90.03 | -- | -- | -- | -- | -- | -- | 0.0012 | -- | -- | -- | 59.45 | -- | -34.05 | -- |
Silo Pharma Inc | 72.12k | -3.53m | 5.63m | 3.00 | -- | 1.08 | -- | 78.13 | -1.18 | -1.20 | 0.024 | 1.87 | 0.008 | -- | -- | 24,040.00 | -39.26 | -24.90 | -43.11 | -26.39 | 91.90 | 82.79 | -4,889.57 | -2,757.85 | -- | -- | 0.00 | -- | 0.00 | -- | 7.07 | -- | -- | -- |
Lipella Pharmaceuticals Inc | 477.45k | -4.74m | 5.71m | 5.00 | -- | 2.06 | -- | 11.96 | -0.7633 | -0.7633 | 0.0747 | 0.3638 | 0.1232 | -- | 6.25 | 95,490.00 | -122.37 | -- | -146.33 | -- | -- | -- | -993.39 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
Sonnet Biotherapeutics Holdings Inc | 92.74k | -8.43m | 5.73m | 12.00 | -- | 1.88 | -- | 61.75 | -5.28 | -5.28 | 0.0315 | 0.9813 | 0.0097 | -- | 0.2248 | 7,728.33 | -87.68 | -- | -194.11 | -- | -- | -- | -9,086.22 | -- | -- | -138.21 | 0.00 | -- | -57.76 | -- | 36.64 | -- | -- | -- |
Hoth Therapeutics Inc | 0.00 | -7.70m | 5.77m | 2.00 | -- | 0.6634 | -- | -- | -2.02 | -2.02 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -70.17 | -157.07 | -77.15 | -177.32 | -- | -- | -- | -- | -- | -50.67 | 0.00 | -- | -- | -- | 31.01 | -- | -- | -- |
HST Global Inc | 0.00 | -146.22k | 5.77m | 1.00 | -- | -- | -- | -- | -0.0279 | -0.0279 | 0.00 | -0.1128 | 0.00 | -- | -- | -- | -17,002.33 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -26.54 | -- | -- | -- | -- | -0.7858 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
HighTower Advisors LLCas of 31 Mar 2024 | 99.43k | 4.42% |
Ethos Financial Group LLCas of 31 Mar 2024 | 24.81k | 1.10% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 7.11k | 0.32% |
Tower Research Capital LLCas of 31 Mar 2024 | 3.94k | 0.18% |
FNY Capital Management LPas of 31 Mar 2024 | 3.00k | 0.13% |
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 9.00 | 0.00% |
UBS Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |